Tracked deals
90
90 tracked deals across 2024.
Biotechnology Acquisitions in 2024
Buyer mix
Mixed buyer set
75 strategic · 39 pe
Top trend
Volume peaked in 2022
114 tracked deals announced in 2022.
Buyer Snapshot
Top Buyers
Illustrative buyers pulled from tracked transactions on this page. This table is capped and intentionally non-exhaustive.
| Buyer | # Deals | Focus | Type |
|---|---|---|---|
| Ampersand Capital Partners | 6 | Middle-market private equity firm focused on growth-orien... | PE |
| AbbVie | 2 | Global biopharmaceutical company focused on discovery, de... | Strategic |
| AstraZeneca | 2 | Global biopharmaceutical company focused on discovery, de... | Strategic |
| Branded Legacy, Inc. | 2 | OTC-listed pharmaceutical biotechnology company operating... | Strategic |
| Calibre Scientific | 2 | Diversified global provider of life‑science reagents, too... | Strategic |
| Celltrion | 2 | South Korean biopharmaceutical company focused on develop... | Strategic |
| Ginkgo Bioworks | 2 | Public company building a cell‑programming and biosecurit... | Strategic |
| Iron Path Capital | 2 | Private equity firm focused on building businesses in hea... | PE |
| Johnson & Johnson | 2 | Global diversified healthcare company developing pharmace... | Strategic |
| Novo Holdings | 2 | Life-sciences and life-investment holding company managin... | PE |
Acquisition Volume in Biotechnology in 2024 by Year
Last 10 years
Actual
Full-year estimate
Supporting Data
Recent Transactions
-
December 24, 2024
- Buyer
- Altaris, LLC
- Target
- Advanced Therapies (U.S. and U.K. operations of WuXi AppTec's Advanced Therapies Unit), OXGENE
- Seller
- WuXi AppTec
- Industry
- Biotechnology
- Location
- Pennsylvania, United States
- Type
- Addon
Altaris, a New York-based healthcare-focused investment firm, acquired the U.S. and U.K. operations of WuXi AppTec's Advanced Therapies unit (including OXGENE). Advanced Therapies will be renamed and headquartered in the United States and Altaris intends to combine it with its recently acquired Minaris Regenerative Medicine to form Minaris Advanced Therapies, expanding cell-therapy CDMO capabilities and global footprint.
-
December 12, 2024
- Buyer
- Tenpoint Therapeutics Limited
- Target
- Visus Therapeutics, Inc.
- Industry
- Biotechnology
- Location
- Washington, United States
- Type
- Buyout
Tenpoint Therapeutics Ltd. and Visus Therapeutics, Inc. completed a merger to combine their ophthalmic drug development programs, bringing the late-stage presbyopia candidate BRIMOCHOL PF together with Tenpoint’s broader aging-eye pipeline. The combined company is launching a crossover financing round with participation from institutional investors to support an NDA filing and a planned US commercial launch of BRIMOCHOL PF in the 1H of 2026. Henric Bjarke was named CEO of the merged company.
-
December 11, 2024
- Buyer
- Cormorant Asset Management, ARCH Venture Partners, Atlas Venture, Newpath Partners, 5AM Ventures, DCVC Bio, F-Prime Capital, GV (Google Ventures), Janus Henderson Investors, Mubadala Capital, Omega Funds, Sixth Street, Sofinnova Partners, T. Rowe Price, Wellington Management, Alexandria Venture Investments, Casdin Capital, Menlo Ventures, Wilson Sonsini Goodrich & Rosati
- Target
- Chroma Medicine, Nvelop Therapeutics
- Industry
- Biotechnology
- Location
- Massachusetts, United States
- Type
- Growth capital
Chroma Medicine and Nvelop Therapeutics have merged to form nChroma Bio and completed an oversubscribed $75 million financing led by Cormorant Asset Management, ARCH Venture Partners, Atlas Venture and Newpath Partners. The combined company will advance a pipeline built on epigenetic editing and non-viral, programmable in vivo delivery, with lead candidate CRMA-1001 targeted at chronic hepatitis B and D and a planned clinical trial application submission in 2025.
-
December 11, 2024
- Buyer
- AbbVie
- Target
- Aliada Therapeutics
- Seller
- RA Capital Management, LP, Aliada Therapeutics shareholders (all outstanding equity)
- Industry
- Biotechnology
- Location
- United States
- Type
- Buyout
AbbVie completed its $1.4 billion cash acquisition of RA Capital Management portfolio company Aliada Therapeutics. The deal adds ALIA-1758, an anti-pyroglutamate amyloid beta (3pE-Aβ) antibody in Phase 1 for Alzheimer’s disease, and Aliada’s blood-brain barrier (BBB)-crossing MODEL delivery platform to AbbVie’s neuroscience pipeline.
-
December 4, 2024
- Buyer
- Ampersand Capital Partners
- Target
- VIVEbiotech
- Industry
- Biotechnology
- Location
- Gipuzkoa, Spain
- Type
- Growth capital
Ampersand Capital Partners has made a growth equity investment in VIVEbiotech to support expansion of the company’s lentiviral vector development and GMP manufacturing capabilities in San Sebastián, Gipuzkoa, Spain. The investment will fund capacity growth and execution of VIVEbiotech’s pipeline of customer projects for cell and gene therapy developers, and industry veteran Dr. Stefan Beyer has been named Chairman.
-
December 2, 2024
- Buyer
- Ampersand Capital Partners
- Target
- Gannet BioChem
- Seller
- Nektar Therapeutics
- Industry
- Biotechnology
- Location
- Alabama, United States
- Type
- Divestiture
Ampersand Capital Partners has completed the acquisition of Nektar Therapeutics' PEGylation reagent manufacturing business and launched the new Ampersand portfolio company, Gannet BioChem, operating from a 124,000 sq. ft. FDA‑inspected facility in Huntsville, Alabama. The transaction represents a divestiture by Nektar and creates an independent specialty CDMO focused on development, scaling, and GMP production of polyethylene glycol (PEG) reagents for clinical and commercial biopharmaceutical customers.
-
November 28, 2024
- Buyer
- Roche Holdings, Inc.
- Target
- Poseida Therapeutics, Inc.
- Seller
- Poseida Therapeutics stockholders
- Industry
- Biotechnology
- Location
- California, United States
- Type
- Buyout
Roche Holdings, Inc. has agreed to acquire San Diego-based Poseida Therapeutics for $9.00 per share in cash plus a contingent value right (CVR) for up to $4.00 per share, representing an aggregate equity value of up to $1.5 billion. The acquisition will bring Poseida's non-viral gene-editing platforms, allogeneic TSCM-rich CAR-T programs and in-house GMP cell therapy manufacturing into Roche's Pharmaceuticals Division to establish a new core capability in allogeneic cell therapy.
-
November 25, 2024
- Buyer
- Novo Holdings
- Target
- Benchmark Genetics
- Seller
- Benchmark Holdings plc
- Industry
- Biotechnology
- Location
- Norway
- Type
- Buyout
Novo Holdings agreed to acquire Benchmark Genetics from Benchmark Holdings plc for an enterprise value of up to £260 million. Completion is expected in the first quarter of 2025, subject to shareholder approval and regulatory clearances, with initial consideration of £230 million plus up to £30 million contingent on revenue thresholds.
-
November 21, 2024
- Buyer
- Standard BioTools Inc.
- Target
- Sengenics Corporation Pte Ltd
- Seller
- Summa Equity
- Industry
- Biotechnology
- Location
- Singapore
- Type
- Buyout
Standard BioTools Inc. has acquired Sengenics Corporation Pte Ltd, a Summa Equity portfolio company, to broaden its proteomics and antibody‑profiling capabilities. The deal will integrate Sengenics' KREX™ immunoproteomics and i-OME™ Discovery platform with Standard BioTools' SomaScan/proteomics offerings to enhance biomarker discovery and accelerate drug development.
-
November 14, 2024
- Buyer
- Celltrion, Celltrion Healthcare Hungary Kft.
- Target
- iQone Healthcare Switzerland
- Industry
- Biotechnology
- Location
- Switzerland
- Type
- Buyout
Celltrion announced it will acquire iQone Healthcare Switzerland, a specialty pharmaceutical distributor, sales and marketing business in Switzerland. The acquisition is expected to close by Q4 2024 and will make iQone Healthcare Switzerland a wholly owned subsidiary of Celltrion Healthcare Hungary Kft., supporting Celltrion’s European commercialization strategy.
-
November 13, 2024
- Buyer
- Cullgen Inc.
- Target
- Pulmatrix, Inc., Cullgen Inc.
- Industry
- Biotechnology
- Location
- California, United States
- Type
- Buyout
Pulmatrix announced a proposed merger with Cullgen to create a Nasdaq-listed biopharmaceutical company focused on targeted protein degradation, including three degrader programs in or about to begin Phase 1 clinical trials. The combined company is expected to operate as Cullgen Inc. headquartered in San Diego, California, with closing expected by end of March 2025 subject to approvals. As part of the merger agreement, Pulmatrix plans to divest certain assets, and Pulmatrix stockholders are expected to receive a special cash dividend contingent on net cash at closing.
-
November 13, 2024
- Buyer
- Atlantic Coastal Acquisition Corp. II, Celltrion
- Target
- Abpro Corporation
- Industry
- Biotechnology
- Location
- Massachusetts, United States
- Type
- Buyout
Abpro Corporation and Atlantic Coastal Acquisition Corp. II completed their business combination and the combined company will operate as Abpro Holdings, Inc., with Abpro Corporation as a wholly owned subsidiary. The company is expected to begin trading on Nasdaq under the ticker ABP (and ABPWW for warrants); South Korea's Celltrion participated in a $5.0 million PIPE and appointed Soo Young Lee to Abpro's board.
-
November 8, 2024
- Buyer
- ARCHIMED
- Target
- SeqCenter
- Industry
- Biotechnology
- Location
- Pennsylvania, United States
- Type
- Buyout
Global healthcare private equity firm ARCHIMED has acquired SeqCenter, a Pittsburgh, Pennsylvania-based provider of next-generation DNA and RNA sequencing, through its MED Rise fund. ARCHIMED will leverage its MedValue playbook to accelerate SeqCenter's internationalization in Europe and Asia and support further development of advanced sequencing technologies; SeqCenter's founder rolled over a significant portion of his proceeds into the business.
-
November 7, 2024
- Buyer
- GHO Capital Partners LLP, Ampersand Capital Partners
- Target
- Avid Bioservices
- Seller
- Avid Bioservices stockholders
- Industry
- Biotechnology
- Location
- California, United States
- Type
- Buyout
GHO Capital Partners and Ampersand Capital Partners have completed the acquisition of Avid Bioservices, a dedicated biologics CDMO, in an all-cash transaction valued at approximately $1.1 billion. The transaction takes Avid private (shareholders received $12.50 per share) and positions the company for capability expansion, geographic reach and accelerated growth under the new PE ownership.
-
- Buyer
- Microbiologics
- Target
- SensID (SensID GmbH)
- Industry
- Biotechnology
- Location
- Mecklenburg-Vorpommern, Germany
- Type
- Buyout
Microbiologics has acquired SensID, a Rostock, Germany-based maker of reference materials and quality controls for molecular diagnostics, marking Microbiologics' first location outside the United States. The deal expands Microbiologics' capabilities into oncology and precision medicine and combines both companies' expertise to broaden diagnostic quality-control offerings for diagnostic developers and clinical labs.
-
November 5, 2024
- Buyer
- Miura Partners
- Target
- HTBA (HealthTech BioActives)
- Industry
- Biotechnology
- Location
- Catalonia, Spain
- Type
- Buyout
Miura Partners has signed an agreement to acquire HTBA (HealthTech BioActives), a Barcelona-headquartered producer of flavonoids and active vitamin B12 used across pharmaceutical, nutraceutical, food & beverage and animal nutrition markets. Miura will pursue organic and inorganic initiatives to consolidate HTBA as a leading platform for natural ingredients; the deal is the third investment from Miura Fund IV and is pending approval from the Spanish regulator.
-
- Buyer
- Huons Co., Ltd.
- Target
- PanGen Biotech Inc.
- Seller
- CG Invites
- Industry
- Biotechnology
- Location
- Gyeonggi-do, South Korea
- Type
- Buyout
Huons Co., Ltd. agreed to acquire 2,647,378 shares and newly issued shares in PanGen Biotech Inc. for KRW 14.3 billion, taking a 31.53% stake and becoming PanGen's largest shareholder with plans to secure management control and incorporate PanGen as a subsidiary. The deal is intended to strengthen Huons' biopharmaceutical R&D and CDMO manufacturing capabilities, including securing GMP production for human-derived hyaluronidase used to enable subcutaneous delivery of biologics.
-
- Buyer
- Venetian-1 Acquisition Corp., Montrose Capital, OrbiMed, Torrey Pines Investment, Deerfield Management Company, American Financial Group, Heights Capital
- Target
- Lomond Therapeutics, Inc.
- Industry
- Biotechnology
- Location
- Delaware, United States
- Type
- Buyout
Lomond Therapeutics completed a reverse merger with Venetian-1 Acquisition Corp., which changed its name to Lomond Therapeutics Holdings, Inc., and closed a $44 million private placement led by existing and new investors. The financing included participation from OrbiMed, Torrey Pines Investment, Deerfield Management, American Financial Group and Heights Capital and will fund advancement of Lomond’s clinical-stage oncology programs (lomonitinib, lonitoclax and a menin inhibitor).
-
October 29, 2024
- Buyer
- Quris-AI
- Target
- Nortis (formerly Numa Biosciences, Inc.)
- Industry
- Biotechnology
- Location
- Washington, United States
- Type
- Buyout
Quris-AI has acquired the assets of Nortis (formerly Numa Biosciences) to integrate Nortis's Kidney-on-Chip microphysiology systems into Quris-AI's Bio-AI clinical prediction platform. The acquisition will combine Nortis's validated in-vitro kidney models with Quris-AI's machine-learning models and expand access to publicly funded MPS data while continuing collaborations with research institutes, the FDA and pharmaceutical partners.
-
October 21, 2024
- Buyer
- Axol Bioscience Ltd.
- Target
- Phenocell SAS
- Industry
- Biotechnology
- Location
- Provence-Alpes-Côte d'Azur, France
- Type
- Buyout
Axol Bioscience Ltd. has fully acquired Phenocell SAS, adding Phenocell’s iPSC-derived skin and retinal cell lines and custom bioassay services to Axol’s drug discovery product portfolio. The acquisition expands Axol’s capabilities into ophthalmology and dermatology (including AMD and cosmetics testing); financial terms were not disclosed.
-
- Buyer
- Vizgen, Inc.
- Target
- Ultivue, Inc.
- Industry
- Biotechnology
- Location
- Massachusetts, United States
- Type
- Buyout
Vizgen and Ultivue have merged to create a single spatial biology company that combines Vizgen’s MERFISH single-cell spatial genomics platform with Ultivue’s InSituPlex assays and STARVUE proteomic/AI capabilities. Rob Carson (former CEO of Ultivue) will serve as President and CEO of the combined Vizgen, and the transaction was completed alongside Vizgen’s Series D financing backed by investors including ARCH Venture Partners, Northpond Ventures and Tao Capital Partners.
-
October 8, 2024
- Buyer
- SK bioscience
- Target
- Fina Biosolutions (FinaBio)
- Industry
- Biotechnology
- Location
- Maryland, United States
- Type
- Growth capital
SK bioscience has invested USD 3 million to acquire a stake in Fina Biosolutions (FinaBio), a Rockville, Maryland–based developer of conjugate vaccine technologies and CRM197 protein manufacturing. The strategic investment makes SK bioscience FinaBio's first strategic investor and is intended to accelerate commercialization of FinaBio's EcoCRM and conjugation technologies while enhancing SK bioscience's vaccine development and manufacturing capabilities.
-
October 7, 2024
- Buyer
- Calibre Scientific
- Target
- Molecular Research Center, Inc.
- Industry
- Biotechnology
- Location
- Ohio, United States
- Type
- Buyout
Calibre Scientific has acquired Molecular Research Center, Inc. (MRC), an Ohio-based developer and manufacturer of reagents and kits for RNA and DNA isolation and analysis. The acquisition expands Calibre Scientific's life‑science reagent and molecular biology product offering and strengthens its capabilities in nucleic acid isolation technologies.
-
October 7, 2024
- Buyer
- HealthQuest Capital, Great Point Partners
- Target
- Cellipont Bioservices
- Industry
- Biotechnology
- Location
- Texas, United States
- Type
- Growth capital
Cellipont Bioservices named Darren Head as CEO and announced a minority growth equity investment from HealthQuest Capital, with majority investor Great Point Partners also participating. The capital and leadership transition are intended to support Cellipont’s expansion of cell-therapy CDMO capabilities and operational growth.
-
October 2, 2024
- Buyer
- Bruker Corporation
- Target
- Dynamic Biosensors GmbH
- Industry
- Biotechnology
- Location
- Bavaria, Germany
- Type
- Buyout
Bruker Corporation has acquired Dynamic Biosensors GmbH, a Munich-based developer of single-cell interaction cytometry and biosensor instruments, to strengthen Bruker’s biosensors portfolio. The deal combines Dynamic Biosensors’ heliXcyto and heliX+ technologies with Bruker’s high-throughput SPR systems to expand capabilities and product offerings for drug discovery and biopharma research; financial terms were not disclosed.
-
September 29, 2024
- Buyer
- Valerio Therapeutics S.A., Valour Bio
- Target
- Emglev Therapeutics
- Seller
- Shareholders of Emglev Therapeutics
- Industry
- Biotechnology
- Location
- Île-de-France, France
- Type
- Buyout
Valerio Therapeutics S.A. completed the acquisition of Emglev Therapeutics on September 29, 2024, transferring Emglev's proprietary synthetic single-domain antibody (sdAb) platform into a newly formed Valerio subsidiary, Valour Bio. The deal was structured as a cash sale of shares combined with a contribution-in-kind (Emglev shares exchanged for Valour Bio shares), making Emglev shareholders shareholders of Valour Bio and positioning Valour Bio to advance sdAb discovery and development across oncology and inflammatory/autoimmune indications.
-
September 28, 2024
- Buyer
- AVANT BIO, Avant Bio Fund II LP
- Target
- Nomic Bio, PathPresenter, PL BioScience GmbH
- Industry
- Biotechnology
- Location
- Multiple (Canada; United States; Germany)
- Type
- Growth capital
Growth equity firm AVANT BIO (Avant Bio Fund II LP) participated in three financing rounds: it joined Nomic Bio’s oversubscribed Series B, led PathPresenter’s $7.5M Series A, and joined PL BioScience’s €7.8M Series A. The investments support commercialization, scale-up of production and adoption of life‑science and healthtech solutions across proteomics, digital pathology, and xeno‑free cell culture media.
-
September 25, 2024
- Buyer
- Molecular Designs
- Target
- Lamda Biotech
- Industry
- Biotechnology
- Location
- Missouri, United States
- Type
- Buyout
Molecular Designs, a Birmingham-based provider of PCR assays and related reagents and equipment, has acquired Lamda Biotech, a St. Louis provider of molecular biology research products and kits. The deal will expand Molecular Designs’ product portfolio and manufacturing capacity while broadening access to academic research and pharmaceutical customers and strengthening R&D and technical talent.
-
September 24, 2024
- Buyer
- eMolecules, Inc.
- Target
- Synple Chem AG
- Industry
- Biotechnology
- Location
- Zurich, Switzerland
- Type
- Addon
eMolecules, a San Diego-based provider of a chemical compound search-and-fulfillment platform and a portfolio company of Avista Healthcare Partners, has acquired Synple Chem AG, an automated chemical synthesis systems and services provider headquartered near Zurich, Switzerland. The acquisition adds Synple's automation technology and a virtual compound library of more than 7 trillion tractable compounds to eMolecules' existing offering, expanding its capabilities as a one-stop shop for compound procurement, management and automation for drug discovery customers.
-
September 10, 2024
- Buyer
- Adelis Equity Partners
- Target
- IonOpticks
- Industry
- Biotechnology
- Location
- Victoria, Australia
- Type
- Buyout
Adelis Equity Partners has taken a majority, controlling stake in IonOpticks, a fast-growing developer and manufacturer of high-performance chromatography solutions for LC‑MS proteomics. The founders and management are co-investors; the investment will fund IonOpticks' global expansion, product development, and support future acquisitions as the company scales its commercial footprint.
-
September 5, 2024
- Buyer
- PD Theranostics (PDTx), Lucius Partners
- Target
- Ovation.io
- Industry
- Biotechnology
- Location
- Massachusetts, United States
- Type
- Buyout
PD Theranostics, a Lucius Partners portfolio company, has completed a merger with Ovation.io to create a multiomics data company that combines Ovation's population-scale biobank with PDTx's high-dimensional imaging and multiomic platform. The combined business will link sequencing, imaging, and longitudinal clinical data to accelerate biomarker and target discovery for drug development and clinical research.
-
- Buyer
- Keen Vision Acquisition Corporation
- Target
- Medera Inc.
- Industry
- Biotechnology
- Location
- New Jersey, United States
- Type
- Buyout
Keen Vision Acquisition Corporation (KVAC) entered into a definitive merger agreement with clinical-stage biotechnology company Medera Inc. to take Medera public on Nasdaq, expected to close in the fourth quarter of 2024. The business combination is expected to provide funds that will accelerate Medera’s three most advanced AAV-based gene therapy programs.
-
September 3, 2024
- Buyer
- Leinco Technologies, Ampersand Capital Partners
- Target
- QED Biosciences
- Seller
- Genovis
- Industry
- Biotechnology
- Location
- California, United States
- Type
- Addon
Leinco Technologies, a portfolio company backed by Ampersand Capital Partners, has acquired Genovis-owned QED Biosciences to expand its catalog of antibodies, recombinant proteins and IVD raw materials. The deal transfers Genovis' antibody business to Leinco and strengthens Leinco's antibody development and IVD support capabilities for research and diagnostics customers worldwide.
-
September 2, 2024
- Buyer
- Asahi Kasei Corporation
- Target
- Calliditas Therapeutics AB
- Industry
- Biotechnology
- Location
- Sweden
- Type
- Buyout
Asahi Kasei Corporation completed a recommended public cash offer for Calliditas Therapeutics AB, acquiring 93.30% of the outstanding shares and ADSs as of settlement. Asahi Kasei intends to convert ADSs, commence a compulsory buy-out of remaining shares, and pursue delisting of Calliditas from Nasdaq Stockholm and suspension/delisting of ADSs in the U.S.
-
August 29, 2024
- Buyer
- VION Biosciences, Iron Path Capital
- Target
- Ansh Labs
- Industry
- Biotechnology
- Location
- Texas, United States
- Type
- Addon
VION Biosciences, the life-science platform backed by Iron Path Capital, has acquired Ansh Labs, an immunoassay development and reagent manufacturer based in Houston, Texas. The add-on expands VION's diagnostics capabilities — adding GMP IVD manufacturing and ISO 13485 certification — and broadens the platform's product and service offerings for clinical diagnostics, research, and pharmaceutical development.
-
August 22, 2024
- Buyer
- VION Biosciences, Iron Path Capital
- Target
- Echelon Biosciences
- Seller
- Bert V. Israelsen
- Industry
- Biotechnology
- Location
- Utah, United States
- Type
- Addon
VION Biosciences, the life-science platform backed by Iron Path Capital, has acquired Salt Lake City-based Echelon Biosciences, a specialist supplier of lipid-based excipients and lipid nanoparticles. The add-on strengthens VION's capabilities in lipid synthesis and lipid nanoparticle technology to support mRNA and gene-therapy development and advances the platform toward drug manufacturing while keeping Echelon’s leadership and operations intact.
-
August 16, 2024
- Buyer
- Energy Fuels Inc.
- Target
- RadTran LLC
- Industry
- Biotechnology
- Location
- Colorado, United States
- Type
- Buyout
Energy Fuels Inc. acquired RadTran LLC, a private specialist in radioisotope separation, to accelerate development and production of medical isotopes (notably Ra-226 and Ra-228) used in targeted alpha therapies for cancer. The deal (closed August 16, 2024) paid $1.5M cash, $1.5M in shares, a 2% royalty on future radium revenues and up to $14M in additional cash/shares tied to milestones; RadTran's CEO Saleem Drera joins Energy Fuels to lead radioisotope efforts.
-
August 12, 2024
- Buyer
- TenX Keane Acquisition
- Target
- Citius Oncology, Inc., Citius Pharmaceuticals’ wholly owned oncology subsidiary
- Seller
- Citius Pharmaceuticals, Inc.
- Industry
- Biotechnology
- Location
- New Jersey, United States
- Type
- Buyout
TenX Keane Acquisition is merging with Citius Pharmaceuticals’ wholly owned oncology subsidiary to create a new publicly traded company, Citius Oncology, Inc. (expected Nasdaq ticker CTOR), with Citius Pharma retaining majority control (about 90%). The transaction is positioned to support commercialization of LYMPHIR and exploration of additional targeted oncology assets.
-
August 7, 2024
- Buyer
- Pharmacosmos A/S, Pharmacosmos Therapeutics Inc.
- Target
- G1 Therapeutics, Inc.
- Seller
- G1 Therapeutics' shareholders
- Industry
- Biotechnology
- Location
- North Carolina, United States
- Type
- Buyout
Pharmacosmos A/S, through its U.S. affiliate Pharmacosmos Therapeutics Inc., agreed to acquire all outstanding shares of G1 Therapeutics, Inc. for $7.15 per share in cash, implying an approximate equity value of $405 million. The deal brings G1's FDA-approved oncology product COSELA into Pharmacosmos' commercial portfolio to accelerate patient access and expand Pharmacosmos' presence in oncology and supportive care.
-
August 6, 2024
- Buyer
- Boehringer Ingelheim
- Target
- Nerio Therapeutics, Inc.
- Seller
- Avalon Ventures, Bregua Corporation, Correlation Ventures, Alexandria Venture Investments, Viva BioInnovator (VBI)
- Industry
- Biotechnology
- Location
- California, United States
- Type
- Buyout
Boehringer Ingelheim agreed to acquire Nerio Therapeutics, a San Diego-based preclinical biotech focused on PTPN2/N1 phosphatase inhibitors for immuno-oncology, for up to $1.3 billion. Nerio was invested/incubated by Viva BioInnovator and backed by a syndicate including Avalon Ventures; the deal is intended to accelerate development of Nerio’s preclinical program as a cornerstone of Boehringer’s immuno-oncology portfolio.
-
August 1, 2024
- Buyer
- Novo Holdings
- Target
- Oxford Nanopore Technologies
- Industry
- Biotechnology
- Location
- England, United Kingdom
- Type
- Growth capital
Novo Holdings has invested £50 million in UK-listed Oxford Nanopore Technologies via an equity issue and intends to make further share purchases in the secondary market. The investment is intended to support Oxford Nanopore's commercial growth and capability expansion in biopharmaceutical and biomanufacturing markets.
-
August 1, 2024
- Buyer
- Otsuka Pharmaceutical Co., Ltd., Otsuka America, Inc.
- Target
- Jnana Therapeutics Inc.
- Seller
- Shareholders of Jnana Therapeutics
- Industry
- Biotechnology
- Location
- Massachusetts, United States
- Type
- Buyout
Otsuka Pharmaceutical Co., Ltd. will acquire clinical-stage biotech Jnana Therapeutics, making it a wholly owned subsidiary via Otsuka America, Inc. The deal values Jnana at $800 million in upfront cash plus up to $325 million in development and regulatory milestones and is intended to add Jnana's RAPID chemoproteomics platform and lead program JNT-517 (a potential oral PKU therapy) to Otsuka's specialty and autoimmune pipeline.
-
July 18, 2024
- Buyer
- Dechra Pharmaceuticals Limited
- Target
- Invetx Inc.
- Seller
- Novo Holdings A/S, F-Prime Capital, GV, Eight Roads, Anterra Capital, Casdin Capital, Tekla Capital Management
- Industry
- Biotechnology
- Location
- Massachusetts, United States
- Type
- Buyout
Dechra Pharmaceuticals Limited has agreed to acquire Boston-based Invetx Inc., a developer of species-specific monoclonal antibody therapeutics for companion animals, for up to $520 million on a cash-free, debt-free basis, subject to customary approvals. The deal gives Dechra access to Invetx's pipeline and half-life extension platform to expand its specialty veterinary biologics capabilities.
-
July 10, 2024
- Buyer
- Thermo Fisher Scientific Inc.
- Target
- Olink Holding AB (publ)
- Seller
- Summa Equity
- Industry
- Biotechnology
- Location
- Uppsala County, Sweden
- Type
- Buyout
Thermo Fisher Scientific completed the acquisition of Olink Holding AB (publ) via a public cash tender offer at USD 26.00 per share/ADS, buying the proteomics company from shareholders including Summa Equity. The acquisition strengthens Thermo Fisher’s proteomics and protein-analysis capabilities, adding Olink’s high‑multiplex protein detection technology to its life‑science tools portfolio.
-
July 9, 2024
- Buyer
- Illumina, Inc.
- Target
- Fluent BioSciences
- Industry
- Biotechnology
- Location
- Massachusetts, United States
- Type
- Buyout
Illumina, Inc. has acquired Fluent BioSciences to integrate Fluent's PIPseq single-cell technology into Illumina's product portfolio and accelerate its multiomics capabilities. The acquisition, which closed July 9, 2024 and was funded with cash on hand, brings Fluent's accessible, scalable single-cell chemistry and the Fluent team into Illumina to expand end-to-end single-cell solutions for research and applied customers.
-
July 8, 2024
- Buyer
- Eli Lilly and Company
- Target
- Morphic Holding, Inc.
- Seller
- Morphic stockholders
- Industry
- Biotechnology
- Location
- Massachusetts, United States
- Type
- Buyout
Eli Lilly agreed to acquire Morphic Holding, Inc. for $57 per share (approximately $3.2 billion) to expand its immunology and gastroenterology pipeline with Morphic's oral integrin therapies, including MORF-057. Lilly commenced a tender offer that was completed (with subsequent second-step merger) and the transaction closed in August 2024.
-
- Buyer
- Genexine
- Target
- EPD Biotherapeutics (EPD Bio)
- Industry
- Biotechnology
- Location
- South Korea
- Type
- Buyout
Genexine, a clinical-stage Korean biopharmaceutical company, announced a small-scale merger with EPD Biotherapeutics (EPD Bio) to strengthen its drug development pipeline. The merger is intended to add PROTAC/bioPROTAC (bioPROTAC via EPDegTM mRNA-LNP) technology talent and expand Genexine’s R&D capabilities, with EPD Bio’s founder joining Genexine to lead R&D.
-
July 1, 2024
- Buyer
- Genezen, Ampersand Capital Partners
- Target
- uniQure commercial gene therapy manufacturing operations (Lexington, MA)
- Seller
- uniQure
- Industry
- Biotechnology
- Location
- Massachusetts, United States
- Type
- Divestiture
Genezen has acquired uniQure's commercial gene therapy manufacturing operations and licensed viral-vector facility in Lexington, Massachusetts. The deal (funded in part by growth equity from Ampersand Capital Partners) transfers a commercially licensed AAV-capable manufacturing site and team to Genezen and includes strategic supply agreements to support uniQure's clinical portfolio and CSL Behring's commercial HEMGENIX product.
-
- Buyer
- Partners Group
- Target
- FairJourney Biologics
- Seller
- GHO Capital Partners LLP
- Industry
- Biotechnology
- Location
- Porto, Portugal
- Type
- Buyout
Partners Group has acquired a majority stake in FairJourney Biologics from GHO Capital; GHO will reinvest as a minority investor and founder António Parada remains invested. The transaction will further capitalise FairJourney to expand its antibody discovery and development capabilities, scientific leadership and global footprint.
-
June 27, 2024
- Buyer
- AbbVie
- Target
- Celsius Therapeutics, Inc.
- Industry
- Biotechnology
- Location
- Massachusetts, United States
- Type
- Buyout
AbbVie has acquired Celsius Therapeutics, a Cambridge-based clinical-stage biotechnology company, for $250 million in cash. The acquisition adds Celsius' lead anti-TREM1 antibody candidate CEL383 to AbbVie’s inflammatory disease pipeline to support development for inflammatory bowel disease (IBD).
Full Export
Purchase this data
Get the full acquisitions list for this page as CSV + XLSX.
Build a buyer list for your Biotechnology deal
Find buyers actively acquiring biotechnology companies.
Related Acquisition Pages
Biotechnology Buyers & Acquisitions
Biotechnology Buyers & Acquisitions in Canada
Private Equity-Backed Biotechnology Buyers
Biotechnology Acquisitions in Pennsylvania
Biotechnology Acquisitions in Washington
Biotechnology Acquisitions in Massachusetts
Biotechnology Acquisitions in Alabama
Biotechnology Acquisitions in California
Biotechnology Acquisitions in Delaware